Abstract
Phospholamban (PLN) is the natural inhibitor of the sarco/endoplasmic reticulum Ca2+ ATP-ase (SERCA2a). Heterozygous PLN-R14Del mutation is associated with an arrhythmogenic dilated cardiomyopathy (DCM), whose pathogenesis has been attributed to SERCA2a “super-inhibition”. Test in human induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CM) harvested from a PLN-R14del carrier whether i) Ca2+ dynamics and protein localization were compatible with SERCA2a superinhibition and ii) functional abnormalities could be reverted by pharmacological SERCA2a activation with (PST3093).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
